Cabozantinib,Nivolumab,Ipilimumab
Exelixis,bms
['thanks', 'congrat']
final tweet: huge congrats to &amp; the study team &amp; many thanks to for the opportunity to summarize this impt data. 
@cityofhope & @cityofhopeoc prof w focus on #kidneycancer, #prostatecancer, #bladdercancer & 90s rock. RTs not endorsements. COI: https://t.co/L7ihnCjLz5